Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.

Authors:
Address: HIV Unit, Infectious Diseases Department, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain. aimaz@bellvitgehospital.cat.
Journal:

Publication:

abstract

BACKGROUND:

Structured antiretroviral therapy interruption (TI) is discouraged because of poorer AIDS and non-AIDS-related outcomes, but is often inevitable in clinical practice. Certain strategies could reduce the emergence of resistance mutations related to TI.

METHODS:

A total of 106 HIV-1-infected patients on stable HAART with undetectable plasma viral load were randomized to therapy continuation (n=50) or CD4(+) T-cell-guided TI (n=56). Staggered interruption involved stopping non-nucleoside reverse transcriptase inhibitors (NNRTIs) 7 days before the nucleoside backbone. Genotypic resistance testing (GRT) was performed on proviral DNA from peripheral blood mononuclear cells (PBMCs) at baseline and before each TI, and on plasma RNA after each TI.

RESULTS:

At baseline, GRT on PBMCs detected mutations in nine patients and only two major mutations were identified. GRT on plasma samples performed after TIs showed nucleoside reverse transcriptase inhibitors (NRTI), NNRTI and protease inhibitor major resistance associated mutations in 10/56, 3/46 and 1/8 patients receiving these drugs, respectively. Only in two patients had the same mutations been observed in GRT on PBMCs at baseline. Three patients presented virological failure after resumption of therapy, all receiving NNRTIs. In one of them, resistance mutations detected at failure had been also observed previously in GRT on plasma after TI.

CONCLUSIONS:

Staggered interruption of NNRTIs 7 days before the nucleoside backbone does not avoid resistance emergence completely, but does not necessarily lead to virological failure after treatment resumption. Plasma HIV-1 RNA genotype after the interruption and the patient's treatment history seem to be more useful than baseline proviral DNA genotype to assess the risk of virological failure after restarting therapy.

Related Articles
HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Int J STD AIDS. 2007
HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B. Int J STD AIDS. 2007 Dec; 18(12):832-4.
Review Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Verh K Acad Geneeskd Belg. 2001
Review Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K. Verh K Acad Geneeskd Belg. 2001; 63(5):447-73.
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Antivir Ther. 2008
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Darwich L, Esteve A, Ruiz L, Bellido R, Clotet B, Martinez-Picado J. Antivir Ther. 2008; 13(7):945-51.
The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.
Antivir Ther. 2003
The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.
Ciancio BC, Trotta MP, Lorenzini P, Forbici F, Visco-Comandini U, Gori C, Bonfigli S, Bellocchi MC, Sette P, D'Arrigo R, et al. Antivir Ther. 2003 Dec; 8(6):611-6.
Review Molecular biological assessment methods and understanding the course of the HIV infection.
APMIS Suppl. 2003
Review Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL. APMIS Suppl. 2003; (114):1-37.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.